Condition 1: End stage renal desease patients who underwent hemodialysis treatment. Condition 2: Intradialytic hypotension. Chronic kidney disease, stage 5 Other hypotension
Conditions
Interventions
Intervention 1: Intervention: Vasopressin nasal spray, 20 micrograms, 30 minutes before the start of hemodialysis start, for 30 days. Intervention 2: Control: Nacl Nasal spary, 30 minutes before the s
Treatment - Drugs
Placebo
Intervention: Vasopressin nasal spray, 20 micrograms, 30 minutes before the start of hemodialysis start, for 30 days
Control: Nacl Nasal spary, 30 minutes before the start of hemodialysis, for 30 days
Sponsors
All costs of this study were be paid by the researcher
Eligibility
Sex/Gender
All
Age
15 Years to 70 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: ESRD patients with known symptomatic episode of intradialytic hypotension in at least 30% of hemodialysis sessions in the 30 days preceding enrollment; Serum sodium levels greater than 140 mEq/L. Exclusion criteria: History of ischemic heart desease; History of cardiovascular events (MI, CVA, ...); Anemia (HB<10 g/dL); Usage of other treatments for intradialytic hypotension at the same time
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Intradialytic Hypotension. Timepoint: Before hemodialysis and 1, 2, 3 ,4 hours after the start of hemodialysis start. Method of measurement: By Mercury sphygmomanometer - A fall in Systolic Blood Pressure by at least 20 mmHg or a decrease in mean arterial pressure by at least 10 mmHg with clinical symptomes of hypotension after onset of hemodialysis.;Saline volume. Timepoint: After intradialytic hypotension occures and needes intervertion. Method of measurement: By the given volume of saline (mL). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Ali Alidadi
Zahedan University of Medical Sciences
Outcome results
None listed